DrugPatentWatch Database Preview
Drugs in Development Information for VS-6063
» See Plans and Pricing
What is the drug development status for VS-6063?
VS-6063 is an investigational drug.
There have been 16 clinical trials for VS-6063.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2020.
The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), and Cancer Research UK.
There are fifteen US patents protecting this investigational drug and one hundred and twenty-six international patents.
Summary for VS-6063
| US Patents | 15 |
| International Patents | 126 |
| US Patent Applications | 88 |
| WIPO Patent Applications | 76 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 1 (2020-11-01) |
| Vendors | 49 |
Recent Clinical Trials for VS-6063
| Title | Sponsor | Phase |
|---|---|---|
| Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Verastem, Inc. | Phase 2 |
| Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma | Thomas Jefferson University | Phase 2 |
| A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer | Verastem, Inc. | Phase 2 |
Clinical Trial Summary for VS-6063
Top disease conditions for VS-6063
Top clinical trial sponsors for VS-6063
US Patents for VS-6063
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VS-6063 | Start Trial | Gene fusions and gene variants associated with cancer | LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) | Start Trial |
| VS-6063 | Start Trial | Methods of diagnosing and treating B cell acute lymphoblastic leukemia | The General Hospital Corporation (Boston, MA) Tufts Medical Center, Inc. (Boston, MA) | Start Trial |
| VS-6063 | Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Start Trial |
| VS-6063 | Start Trial | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | Start Trial |
| VS-6063 | Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| VS-6063 | Start Trial | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | Start Trial |
| VS-6063 | Start Trial | Use of facilitates chromatin transcription complex (FACT) in cancer | Incuron, Inc. (Buffalo, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VS-6063
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VS-6063 | Australia | AU2014254394 | 2033-04-17 | Start Trial |
| VS-6063 | China | CN105378110 | 2033-04-17 | Start Trial |
| VS-6063 | China | CN106414768 | 2033-04-17 | Start Trial |
| VS-6063 | European Patent Office | EP2986736 | 2033-04-17 | Start Trial |
| VS-6063 | European Patent Office | EP3122901 | 2033-04-17 | Start Trial |
| VS-6063 | European Patent Office | EP3438288 | 2033-04-17 | Start Trial |
| VS-6063 | Japan | JP2016518123 | 2033-04-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
